How ephedrine escaped regulation in the United States: A historical review of misuse and associated policy

Health Policy

Volumn 99, Issue 1, 2011, Pages 1-9

  Palamar, Joseph ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Dietary supplements; Drug policy; Ephedra; Ephedrine; History

Indexed keywords

EPHEDRINE; PRESCRIPTION DRUG;

DRUG CONTROL; DRUG MISUSE; HEALTH CARE POLICY; REVIEW; UNITED STATES;

DIETARY SUPPLEMENTS; EPHEDRINE; GOVERNMENT REGULATION; HEALTH POLICY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INAPPROPRIATE PRESCRIBING; LEGISLATION, DRUG; UNITED STATES;

EID: 78649947914     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2010.07.007     Document Type: Review

References (117)

1. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Federal Register 11 February 2004;69.
2. Chen K.K., Schmidt C.F. Ephedrine and related substances. Medicine Monographs XVII 1930, The Williams & Wilkins Company, Baltimore.
3. Chen K.K., Schmidt C.F. The action of ephedrine, an alkaloid from ma huang. Proceedings of the Society for Experimental Biology and Medicine 1924, 21:351-354.
4. Rasmussen N. Making the first anti-depressant: amphetamine in American Medicine. Journal of the History of Medicine and Allied Sciences 2006, 61(3):288-323.
5. Science News Letter. Find drug that will keep sleepy persons wide awake. Science News Letter 1935;28:403.
6. Kampmeier R.H. Ephedrine in allergic migraine. Journal of Allergy 1933, 5:74-75.
7. Christopherson J.B., Broadbent M. Ephedrine and pseudo-ephedrine in asthma, bronchial asthma and enuresis. British Medical Journal 1934, 1(3830):978-979.
8. Albee F.H., Fry S.O. Spinal anesthesia in orthopedic surgery. The American Journal of Surgery 1928, 5(6):608-610.
9. Miller K.E. Public health aspects of unrestricted advertising. American Journal of Public Health 1940, 30:880-886.
10. Scarano J.A. Rapidity of shrinkage and immediate secondary reactions following local applications of ephedrine and benzedrine. Medical Record 1934, 140:602.
11. New York Times. FTC cites concern on cure for asthma. New York Times, 17 November 1939.
12. New York Times. Must drop asthma cure claims. New York Times, 18 May 1940:17.
13. Rasmussen N. On speed: the many lives of amphetamine 2008, New York University Press, New York, NY.
14. Rasmussen N. America's first amphetamine epidemic 1929-1971: a quantitative and qualitative retrospective with implications for the present. American Journal of Public Health 2008, 98(6):974-985.
15. Musto D.F. The American disease: origins of narcotic control 1973, Yale University Press, New Haven.
16. Grinspoon L. The speed culture: amphetamine use and abuse in America 1976, Harvard University Press, Cambridge, MA.
17. Los Angeles Times. Pep drugs are safe if you use with reason. Los Angeles Times, 1 June 1953:15.
18. Scott J. It's not how you play the game, but what pill you take. New York Times 17 October 1971, SM40-50.
19. Plumb K. AMA to study drugs in sports. New York Times 6 June 1957, 1:38.
20. Washington Post. Five categories of stimulants out for games. Washington Post, 31 January 1968.
21. Gutmann M.J. Abuse of ephedrine (ephedrine addiction) in patients with bronchial asthma. International Archives of Allergy & Applied Immunology 1961, 18:140-144.
22. Herridge C.F., A'Brook M.F. Ephedrine psychosis. British Medical Journal 1968, 2(5598):160.
23. Chapple P.A.L. New drugs of addiction. British Medical Journal 1965, 2(5453):108.
24. Johnson J., Milner G. Psychiatric complications of amphetamine substances. Acta Psychiatrica Scandinavica 1966, 42(3):252-263.
25. WHO Expert Committee on Dependence-Producing Drugs Fourteenth Report. WHO Technical Report Series 312 1965, World Health Organization, Geneva.
26. Drug Abuse Control Amendment of 1965, Sec. 5, Pub. L. no. 89-74.
27. WHO Expert Committee on Drug Dependence Sixteenth Report. WHO Technical Report Series 407 1969, World Health Organization, Geneva.
28. Isbell H., Chrusciel T.L. Dependence liability of non-narcotic drugs. Bulletin of the World Health Organization 1970, 43:1-111.
29. Martin W.R., Sloan J.W., Sapira J.D., et al. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clinical Pharmacology and Therapeutics 1971, 12:245-258.
30. Sapira J.D., McDonald R.H. Drug abuse-1970. Disease a Month 1970, 1-47.
31. Spillane J.F. Debating the Controlled Substances Act. Drug and Alcohol Dependence 2004, 76:17-29.
32. Anthony J.C., Trinkoof A.M. Epidemiologic issues pertinent to international regulation of 28 stimulant-hallucinogen drugs. Drug and Alcohol Dependence 1986, 17:193-211.
33. Maronde R.F., Lee P.V., McCarron M.M., et al. A study of prescribing patterns. Medical Care 1971, 9(5):383-395.
34. Retka R.L. Patterns of new drug detection in the Drug Abuse Warning Network. British Journal of Addiction 1978, 73:155-165.
35. Klatt E.C., Montgomery S., Namiki T., et al. Misrepresentation of stimulant street drugs: a decade of experience in an analysis program. Journal of Clinical Toxicology 1986, 24(5):441-450.
36. Jain N.C., Budd R.D., Sneath T.C. Frequency of use or abuse of amphetamine-related drugs. American Journal of Drug and Alcohol Abuse 1979, 6:53-57.
37. Dougherty R.J. Pseudo-speed: look-alikes or pea shooters. New York State Journal of Medicine 1982, 82(1):74-75.
38. Lake C.R., Quirk R.S. CNS stimulants and the look-alike drugs. Psychiatric Clinics of North America 1984, 7(4):689-701.
39. Halpern J.S. Street speed. Journal of Emergency Nursing 1983, 9:224-227.
40. Saxon W. FDA acts to suppress sale of 'recreational stimulants'. New York Times 20 November 1983, 28.
41. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the Future National Survey Results on Drug Use, 1975-2007, Volume I: Secondary School Students (NIH Publication No. 08-6418A). Bethesda, MD: National Institute on Drug Abuse; 2008. [accessed 23.12.08]. http://monitoringthefuture.%20org/pubs/monographs/vol1_2007.pdf.
42. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2007 (NIH Publication No. 08-6418). Bethesda, MD: National Institute on Drug Abuse; 2008. [accessed 23.12.08]. http://monitoringthefuture.org/pubs/monographs/overview2007.pdf.
43. Federal Register. New drug status of OTC combination drug products containing caffeine, phenylpropanolamine, and ephedrine. Federal Register 13 August 1982;47(157):35344-5.
44. Federal Register. Enforcement action under the new drug provisions of the Federal Food, Drug, and Cosmetic Act; certain OTC drug products; advisory opinion. 18 November 1983;48(224):52513-4.
45. FDA Consumer. Shutting down a major source of deadly look-alike drugs-investigators' reports. FDA Consumer; September 1986.
46. Keup W. Use, indications and distribution in different countries of the stimulant and hallucinogenic amphetamine derivatives under consideration by WHO. Drug and Alcohol Dependence 1986, 17:169-192.
47. Siegel R.K. New trends in drug use among youth in California. Bulletin on Narcotics 1985, 2:7-17.
48. Ohio State Board of Pharmacy. Controlled Substances Act, Drug abuse/misuse report, ephedrine; 13 March 1996.
49. CDC Morbidity and Mortality Weekly Report. Adverse events associated with ephedrine-containing products-Texas, December 1993-September 1995. CDC Morbidity and Mortality Weekly Report 1996;45(32):689-93.
50. Chait L.D. Factors influencing the reinforcing and subjective effects of ephedrine in humans. Psychopharmacology 1994, 113(3-4):381-387.
51. Schuh L.M., Heishman S.J., Lewis B., et al. Discriminative stimulant effects of ephedrine and phenylpropanolamine. NIDA Research Monograph, problems of drug dependence, 1994: proceedings of the 56th annual scientific meeting 1995.
52. Frank R.S. The clandestine drug Laboratory situation in the United States. Journal of Forensic Science 1983, 28(1):18-31.
53. Federal Register. Records, reports, imports, exports of precursor, essential chemicals, tableting machines & encapsulating machines. Federal Register 1 August 1989;54:31657-69.
54. Implementation of the Domestic Chemical Diversion Control Act of 1993. Federal Register 60: June 22, 1995.
55. Implementation of the Comprehensive Methamphetamine Control Act of 1996. Federal Register 28 March 2002;67(60).
56. Cunningham J.K., Liu L.M. Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. Addiction 2003, 98:1229-1237.
57. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; proposed amendment of monograph for OTC bronchodilator drug products. Federal Register 13 July 2005;70:133.
58. U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Dietary Supplement Health and Education Act of 1994.
59. Gurley B.J., Gardner S.F., White L.M., et al. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing ephedra sinica (ma huang). Therapeutic Drug Monitoring 1998, 20(4):439-445.
60. White L.M., Gardner S.F., Gurley B.J., et al. Pharmacokinetics and cardiovascular effects of ma-huang (ephedra sinica) in normotensive adults. Journal of Clinical Pharmacology 1997, 37(2):116-122.
61. American Herbal Products Association. Ephedra survey results: 1995-1999. Survey administered & results compiled by Arthur Andersen, LLP, prepared for the AHPA; 28 April 2000.
62. Blanck H.M., Khan L.K., Serdula M.K. Use of nonprescription weight loss products: results from a multistate survey. Journal of the American Medical Association 2001, 286:930-935.
63. Crouch B.I., Caravati E.M., Booth J. Trends in child and teen nonprescription drug abuse reported to a regional poison control center. American Journal of Health-System Pharmacology 2004, 61:1252-1257.
64. Burros M. Eating well: the mysteries and dangers of herbal remedies. New York Times 16 June 1993, C8.
65. Weaver J. In Manhattan, 'smart' bars within bars; clubs in New York riding the 'smart drugs' wave. New York Times 10 June 1992, A1.
66. Lambert B. Nassau to ban sale of herbal stimulant linked to a death. New York Times 17 April 1996, B1-2.
67. Burros M., Jay S. Concern grows over herb that promises a legal high. New York Times 10 April 1996.
68. Claims that Herbal Ecstasy is absolutely safe and will not cause side effects are false, FTC says. Settlement would require safety warning in future ads. FTC News Release; 29 July 1997.
69. Street drug alternatives with ephedrine-products with ephedrine cannot be marketed or labeled as legal ways to get high because of the side effects of the drug. FDA Consumer; June 1996.
70. Food and Drug Administration. FDA talk paper: FDA announces the availability of new ephedrine and 'street drug alternative' documents. T00-15; 31 March 2000.
71. Dennehy C.E., Tsourounis C., Miller A.E. Evaluation of herbal dietary supplements marketed on the Internet for recreational use. The Annals of Pharmacotherapy 2005, 39:1634-1639.
72. Office of Dietary Supplements, National Institutes of Health. Ephedra and ephedrine alkaloids for weight loss and athletic performance; 22 April 2003.
73. Federal Trade Commission. Weight-loss advertising: an analysis of current trends; September 2002.
74. UN Convention against illicit traffic in narcotic drugs and psychotropic substances, 1988. Amendment made by the Commission on Narcotic Drugs, United Nations; 23 November 1992.
75. WHO Expert Committee on Drug Dependence Twenty-ninth report. WHO Technical Report Series 856 1995, World Health Organization, Geneva.
76. WHO Expert Committee on Drug Dependence Thirty-first report. WHO Technical Report Series 887 1999, World Health Organization, Geneva.
77. WHO Expert Committee on Drug Dependence Thirty-second report. WHO Technical Report Series 903 2001, World Health Organization, Geneva.
78. Dietary supplements containing ephedrine alkaloids, proposed rule. Federal Register 4 June 1997;67(107).
79. United States General Accounting Office. Dietary supplements: uncertainties in analyses underlying FDA's proposed rule on ephedrine alkaloids, July 1999. [accessed 23.12.08]. http://www.gao.gov/archive/1999/h299090.pdf.
80. Woolf A.D., Watson W.A., Smolinske S., et al. The severity of toxic reactions to ephedra: comparisons to other botanical products and national trends from 1993-2002. Clinical Toxicology 2005, 43(5):347-355.
81. Kennedy J. Herb and supplement use in the US adult population. Clinical Therapeutics 2005, 27(11):1847-1858.
82. Wilson K.M., Klein J.D., Sesselberg T.S., et al. Use of complementary medicine and dietary supplements among US adolescents. Journal of Adolescent Health 2006, 38:385-394.
83. Gregory A.J.M., Fitch R.W. Sports medicine: performance-enhancing drugs. Pediatric Clinics of North America 2007, 54(4):797-806.
84. The National Collegiate Athletic Association Committee on Competitive Safeguards and Medical Aspects of Sports. NCAA study of substance use habits of college student athletes; January 2006.
85. Green G.A., Uryasz F.D., Petr T.A., et al. NCAA study of substance use and abuse habits of college student-athletes. Clinical Journal of Sports Medicine 2001, 11(1):51-56.
86. H. R. 3065, a bill: Dietary Supplement Information Act, 107th Congress, 1st Session; 9 October 2001.
87. H. R. 3066, a bill: Ephedrine Alkaloid Consumer Protection Act, 107th Congress, 1st Session; 9 October 2001.
88. H. R. 1075, a bill: Ephedra Public Protection Act, 108th Congress, 1st Session, 4 March 2003.
89. S.722, a bill: Dietary Supplement Safety Act of 2003, 108th Congress.
90. H. R. 3377, a bill: Dietary Supplement Access and Awareness Act, 108th Congress.
91. Gugliotta G. Ephedra lawsuits show big increase; stimulant's critics try a new forum. Washington Post 23 July 2000.
92. Weintraub A., Carey J. Commentary: diet pills and pols: a dangerous mix. Business Week 2 September 2002.
93. United States General Accounting Office. Dietary supplements containing ephedra: health risks and FDA's oversight, July 23, 2003. [accessed 23.12.08]. http://www.gao.gov/new.items/d031042t.pdf.
94. Musto D.F. Perception and regulation of drug use: the rise and fall of the tide. Annals of Internal Medicine 1995, 123(6):468-469.
95. Spillane J.F. Cocaine: from modern marvel to modern menace in the United States, 1884-1920 2000, Johns Hopkins University Press, Baltimore and London.
96. Chass M. Pitcher's autopsy lists ephedra as one factor. New York Times 14 March 2003.
97. Kreider R.B. The real truth about ephedra. Muscle & Fitness 1 June 2003.
98. Schmaltz J. Rolling Stone 'hit': the venerable pop culture magazine attacks bodybuilding using few facts but plenty of tired old prejudices. Flex May 2002.
99. Kindred D. There's a right way to get a rate increase. Sporting News 3 March 2003.
100. Kiefer H.M. Americans favor ephedrine ban. Gallop 18 March 2003.
101. Kreider R.B., Burke E.R., Clark J.F., et al. The neurosurgeon in sport: awareness of the risks of heatstroke and dietary supplements (comment). Neurosurgery 2003, 52(1):252-255.
102. Kingston R.L., Borron S.W. The relative safety of ephedra compared with other herbal products: comment. Annals of Internal Medicine 2003, 138(6):385.
103. Boozer C.N., Daly P.A., Homel P., et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. International Journal of Obesity 2002, 26(5):593-604.
104. Issues relating to ephedra-containing dietary supplements: hearings before the Subcommittee on Oversight and Investigations and the Subcommittee on Commerce, Trade, and Consumer Protection of the Committee on Energy and Commerce, House of Representatives, One Hundred Eighth Congress, First Session, July 23 and 24, 2003, Serial No. 108-43.
105. US Supreme Court: Nutraceutical Corp., et al. v. Andrew von Eschenbach, Commissioner, FDA, et al., petition for a Writ of Certiorari to the US Court of Appeals for the Tenth Circuit, No. 06-922; April 2007.
106. US Federal Drug Administration. FDA statement on Tenth Circuit's ruling to uphold FDA decision banning dietary supplements containing ephedrine alkaloids, August 21, 2006. [accessed 23.12.08]. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01434.html.
107. Combat Methamphetamine Epidemic Act 2005. Title VII of Public Law 109-177.
108. S. 256, a bill: Combat Methamphetamine Enhancement Act of 2009, 111th Congress.
109. Whitley B. New worries about meth trends. Christian Science Monitor 19 January 2009.
110. U.S. Food and Drug Administration, Dietary Supplement and Nonprescription Drug Consumer Protection Act. Public Law 109-462, 109th Congress, Dec. 22, 2006.
111. S.3002, a bill: Dietary Supplement Safety Act of 2010, 111th Congress.
112. Saslow L. Nassau restricts herbal aids with stimulant. New York Times 18 August 1996.
113. Howe K. Warning label for ephedra pushed: assembly bill applies to diet supplements. San Francisco Chronicle 2 March 2000.
114. Shekelle P.G., Hardy M.L., Morton S.C., et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. Journal of the American Medical Association 2003, 289:1537-1545.
115. US Department of Health and Human Services, RAND. Ephedra and ephedrine for weight loss and athletic performance enhancement: clinical efficacy and side effects, evidence report/technology assessment, no. 76; 2003.
116. Hallas J., Bjerrum L., Støvring H., et al. Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events. American Journal of Epidemiology 2008, 168(8):966-973.
117. Chen K.K. A comparative study of synthetic and natural ephedrines. Journal of Pharmacology and Experimental Therapeutics 1928, 33(2):237-258.